Transcript
Dr. Naiem Issa: Now, Dr. Offiah, as much as I'd love to keep talking about atopic dermatitis, actually one more thing before we move on, is the chronicity. We like to use something chronically safely, but what I think many people don't know is that with roflumilast cream, there actually was a study in the long-term that showed that twice-weekly dosing, along with the use of emollients, of course, helped to maintain that clearance over time and that itch reduction. So it's nice to be able to tell the parents of these kids on top of that to say, "Look, you don't have to use the medicine every day. We can reduce the medicine to twice per week according to the clinical trials." And they'll be happy to use, quote, unquote, "less medicine," if you will. And who doesn't like that? So that's a nice thing.
Dr. Maureen Offiah: Everybody likes that, because it's a common question that our patients ask us all the time. "Do I have to use this forever? Do I have to apply this every day?" It's really hard for anyone to have to apply any topical medication no matter how great it is, on a daily basis. So having a medication that, one, starts off with that convenient dosing of once daily and they can taper down to twice-weekly for maintenance. As we said, the studies show that. And even so, for some patients, if they're lucky, maybe they could even taper it even more because everyone's different. So that is something that patients definitely welcome. And of course, it's because of that elegant vehicle, the Crodafos, which is a novel vehicle that's bottled in roflumilast, which goes and it helps the skin, what I say, be the best version of itself. So once the skin starts to repair itself, the barrier dysfunction starts to get repaired over time, what you expect is much less flares to come in the future of our patients.
Dr. Naiem Issa: Yes, agreed. Briefly, let's touch on plaque psoriasis. I think here is just a similar thought process. So we won't belabor the point, but with plaque psoriasis, of course, we see the plaques and the scale, and so it's on the other spectrum of immunology than atopic derm, but I think the same points still apply here. There's no difference. You have acute and chronic treatment, and I think steroid stewardship is also going to be very important. And on top of that, PDE4 still is very important for the pathophysiology as well as the itch component of psoriasis, which is a very critical part as well. The only difference here is that we have the 0.3% roflumilast cream once per day versus the 0.15% and the 0.05%. So I think that's an important distinction that some of us may get tripped up, but nonetheless is that we have the availability for plaque psoriasis as well. And it's nice to have the same concepts play out yet again with the same MOA, same active ingredient here. And it's nice to see that.
